Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival

First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer | NEJM

Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial

GeparPiPPa